Carboplatin-based chemotherapy for HER2-low advanced breast cancer
Author Information
Author(s): Li Jingxin, Tang Yijing, Chen Qianying, Lei Sen, Lu Yongkui, Tan Aihua, Xie Weimin
Primary Institution: Guangxi Medical University Cancer Hospital
Hypothesis
Can carboplatin-based first-line treatment improve outcomes in HER2-low advanced breast cancer?
Conclusion
First-line carboplatin-based chemotherapy is effective and tolerable for patients with HER2-low advanced breast cancer.
Supporting Evidence
- The overall objective response rate (ORR) was 42.72%.
- The median progression-free survival (mPFS) was 7.93 months.
- Higher response rates were observed in HER2-low patients compared to HER2-zero patients.
- Adverse reactions were manageable and included neutropenia and anemia.
Takeaway
This study found that using carboplatin as the first treatment for certain breast cancer patients can help them get better faster.
Methodology
Retrospective analysis of 103 HER2-negative metastatic breast cancer patients treated with carboplatin-based chemotherapy.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
The study is retrospective and may not account for all confounding factors.
Participant Demographics
All participants were female, median age 50 years (range 23–75 years).
Statistical Information
P-Value
.003
Confidence Interval
95% CI 1.516–7.977
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website